Ashok Rattan¹*, Erum Khan² and Debadatta Panigrahi³

¹Advisor, Pathkind Labs, Gurgaon, India

*Corresponding Author: Ashok Rattan, Advisor, Pathkind Labs, Gurgaon, India.

Received: March 02, 2022; Published: March 28, 2022

Abstract

Though progress has been made in diagnosis and treatment of Tuberculosis, the slow progress has been compromised by the emergence of drug resistance in M tuberculosis. This drug resistance has been found to occur as point mutation in the target gene of the anti-tubercular drug At present over 15 drugs have been found to be clinically useful for treatment of DR-TB. Thirty-two genes are the target for these drugs and need to be examined for the presence of mutation (resistance). Various laboratory tests have been used for this purpose, but the emergence of Next Generation Sequencing appears to offer an opportunity to take sample from freshly growing M tuberculosis and to simultaneously determine the presence of mutations in any of the 32 genes. With a turnaround time of seven working days, NGS offers the best option to select the most appropriate four drugs which are active against the DR TB that the patient harbours.

Keywords:DR TB; NGS

References

1. “The use of next generation sequencing technologies for the detection of mutations associated with drug resistance in M tuberculosis complex: technology guide”. World Health Organization (2018).
2. “End TB strategy”. World Health Organization (2014).
3. “Global Tuberculosis Report 2020”. World Health Organization (2020).
4. Rattan A., et al. “Multidrug resistant M tuberculosis: Molecular Perspectives”. Emerging Infectious Diseases 4 (1998): 195-209.
5. Genotype MTBDRSl ver 2.0 kit insert.
6. Nguyen TVA., et al. “Bedaquiline resistance: its emergence, mechanism and prevention”. Clinical Infectious Disease 66 (2018): 1625-1630.
7. Nimmo C., et al. “Rapid identification of a M tuberculosis full gene drug profile through whole genome sequencing directly from sputum”. International Infectious Disease 62 (2017): 44-46.
8. Conradie F., et al. “Bedaquiline, pretonamid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis”. The New England Journal of Medicine 382 (2020): 893-902.

Citation

Citation: Ashok Rattan., et al. “Role of Next Generation Sequencing (NGS) in Diagnosis and Personalised Treatment of Drug Resistance Mycobacterium tuberculosis (DR TB)". Acta Scientific Microbiology 5.4 (2022): 166-175.

Copyright

Copyright: © 2022 Ashok Rattan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.